Is CDAK or RYLD a better dividend investment in 2026?

CDAK currently yields 3508.77% with a 5% 5-year dividend growth rate. RYLD yields 12.39% with 5% growth. The better choice depends on your goal: CDAK offers higher current income.

What is the dividend yield difference between CDAK and RYLD?

CDAK has a forward dividend yield of 3508.77% ($2.00/share annually). RYLD yields 12.39% ($1.81/share annually). The yield gap is 3496.38 percentage points.

Home › Compare › CDAK vs RYLD

CDAK vs RYLD: Dividend Comparison 2026

CDAK yields 3508.77% · RYLD yields 12.39%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CDAK wins by $2034141393542.04M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CDAK

● Live price

3508.77%

Share price

$0.06

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2034141393542.08M

Annual income

$1,926,153,862,282,748,700.00

Full CDAK calculator →

RYLD

● Live price

12.39%

Share price

$14.64

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$45.3K

Annual income

$2,682.98

Full RYLD calculator →

Portfolio growth — CDAK vs RYLD

📍 CDAK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CDAK	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CDAK + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CDAK pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDAK

Annual income on $10K today (after 15% tax)

$298,245.61/yr

After 10yr DRIP, annual income (after tax)

$1,637,230,782,940,336,400.00/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,053.44/yr

After 10yr DRIP, annual income (after tax)

$2,280.53/yr

At 15% tax rate, CDAK beats the other by $1,637,230,782,940,334,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDAK + RYLD for your $10,000?

CDAK: 50%RYLD: 50%

100% RYLD50/50100% CDAK

Portfolio after 10yr

$1017070696771.06M

Annual income

$963,076,931,141,375,600.00/yr

Blended yield

94.69%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CDAK right now

CDAK

Analyst Ratings

Buy

Hold

Consensus: Buy

Altman Z

-4.4

Piotroski

2/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDAK buys

RYLD buys

No recent congressional trades found for CDAK or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCDAKRYLD

Forward yield	3508.77% ✓	12.39%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$2034141393542.08M ✓	$45.3K
Annual income after 10y	$1,926,153,862,282,748,700.00 ✓	$2,682.98
Total dividends collected	$2026733119198.63M ✓	$19.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CDAK vs RYLD ($10,000, DRIP)

Year	CDAK Portfolio	CDAK Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$361,577	$350,877.19	$11,939	$1,239.34	+$349.6K → CDAK
2	$12,243,821	$11,856,933.69	$14,158	$1,382.89	+$12.23M → CDAK
3	$388,336,948	$375,236,059.53	$16,682	$1,532.59	+$388.32M → CDAK
4	$11,538,279,357	$11,122,758,822.00	$19,537	$1,687.64	+$11538.26M → CDAK
5	$321,205,540,543	$308,859,581,631.20	$22,752	$1,847.20	+$321205.52M → CDAK
6	$8,379,307,864,544	$8,035,617,936,162.96	$26,355	$2,010.43	+$8379307.84M → CDAK
7	$204,877,671,222,196	$195,911,811,807,134.25	$30,376	$2,176.45	+$204877671.19M → CDAK
8	$4,695,974,086,156,479	$4,476,754,977,948,728.50	$34,847	$2,344.43	+$4695974086.12M → CDAK
9	$100,922,926,410,592,910	$95,898,234,138,405,470.00	$39,800	$2,513.54	+$100922926410.55M → CDAK
10	$2,034,141,393,542,082,800	$1,926,153,862,282,748,700.00	$45,269	$2,682.98	+$2034141393542.04M → CDAK

CDAK vs RYLD: Complete Analysis 2026

CDAK — Stock

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full CDAK Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this CDAK vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDAK vs SCHD CDAK vs JEPI CDAK vs O CDAK vs KO CDAK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.